Genentech

Ocrevus Benefited RRMS Patients Who Responded Poorly to DMTs

Most relapsing-remitting multiple sclerosis (RRMS) patients switching to Ocrevus (ocrelizumab) following suboptimal responses to other disease-modifying therapies (DMTs) show no evidence of disease activity, according to final two-year data from the European-based CASTING Phase 3b trial. These clinical benefits, which entail no relapses or disease progression and no…

Ocrevus Effective in RRMS Patients With Poor Responses to Prior DMTs

Ocrevus (ocrelizumab) safely and effectively prevents relapses and disease progression in relapsing-remitting multiple sclerosis (RRMS) patients who responded poorly to other disease-modifying therapies (DMTs), final two-year data from the CHORDS Phase 3b clinical trial show. Notably, these benefits also were observed among patients who enrolled in the study…

#AANAM – Early Ocrevus Treatment Helps to Protect Nervous System

Editorā€™s note: TheĀ Multiple Sclerosis News TodayĀ team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17ā€“22. GoĀ hereĀ to read the latest stories from the conference. TreatingĀ multiple sclerosis (MS) in its earlier stages with Ocrevus (ocrelizumab) can substantially lower disease activity and lessen damage…

Ocrevus May Delay by 7 Years PPMS Patients’ Need for Wheelchair

Ocrevus (ocrelizumab) treatment may delay the need for a wheelchair by seven years in patients with primary progressive multiple sclerosisĀ (PPMS), a study reports. This delay, drawn from clinical trial data on treatment- versus placebo-group patients and supported by real-world findings, likely translates to long-term benefits for PPMS patients,…

Trial to Examine if Ocrevus Eases Cognitive Fatigue in RRMS

Researchers at the Kessler Foundation, with support from Genentech, are opening a study into howĀ Ocrevus (ocrelizumab) affects cognitive fatigue ā€” the feeling of complete exhaustion after focused concentration ā€” in people with relapsing-remitting multiple sclerosis (RRMS). Cognitive fatigue is a frequent problem with MS, reported in…

FDA Approves Shorter Infusion Time for MS Therapy Ocrevus

The U.S. Food and Drug Administration has approved a shorter infusion time of Ocrevus (ocrelizumab) for treating relapsing or primary progressive multiple sclerosis (MS). Infusion refers to the slow delivery of a therapy directly into the bloodstream over a period of time. The decision shortens the twice-yearly infusion…

Ocrevus Still Reigns for Progressive MS, Spherix Reports, But Challenges Noted

Genentechā€™sĀ OcrevusĀ (ocrelizumab) continues to be the most prescribed treatment for people with progressive forms of multiple sclerosisĀ (MS) amongĀ U.S. neurologists, according to the latestĀ Spherix Global Insightsā€™ report. However, Novartisā€™Ā MayzentĀ (siponimod) ā€œis beginning to close the gapā€ with Ocrevus among those with active secondary progressive MS…

Rituximab Seen to Affect How B-cells Return After Treatment Stops

Rituximab, an investigational B-cell depletion therapy that target CD20 to treat people with multiple sclerosis (MS),Ā has significant effects on the characteristics of B-cells that return after treatment is stopped, with cells being less mature yet more activated toward a pro-inflammatory state, a study showed. Treatment also…

Restarting Rituxan: One Down, and a Lifetime to Go

Last week, I again started my twice-annual infusion of Rituxan (rituximab). After 384 days without my disease-modifying therapy, my team decided I could no longer wait. In its absence, my symptomology had worsened. Halting progression trumped a pandemic, and with personal protective equipment in place, I begin…

#MSVirtual2020 ā€” No Evidence of Disease Activity Seen in Most RRMS Patients After Switching to Ocrevus, Data Show

Switching to Genentechā€™s OcrevusĀ (ocrelizumab) following suboptimal treatment responses significantly lessens symptoms and leads to high rates of no evidence of disease activity in people withĀ relapsing-remitting multiple sclerosisĀ (RRMS), according to data from a Phase 3b clinical trial. That finding, as well as data about patients’ adherence and…